Skip to main content
Log in

New Treatments for Agitation

  • Published:
Psychiatric Quarterly Aims and scope Submit manuscript

Abstract

Acute agitation is a frequent reason for emergency psychiatric intervention. It is important to intervene early to avoid escalation of agitation to aggression. Reducing risk by using effective treatments will result in fewer instances of seclusion and restraint, and fewer injuries to staff and patients. This paper will first review the epidemiology of aggressive behavior and mental disorders, followed by a discussion of assessment and diagnostic considerations. The pathophysiology of safety risk is discussed within the context of the model of the “triune brain.” Pharmacological treatment strategies for acute episodes of agitated behavior will be discussed in detail. This includes newer formulations of novel antipsychotics such as liquids and rapidly disintegrating tablets, as well as intramuscular preparations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Keckich WA: Violence as a manifestation of akathisia. JAMA 240:2185, 1978.

    Google Scholar 

  2. Siris SG: Three cases of akathisia and “acting out.” Journal of Clinical Psychiatry 46:395–397, 1985.

    Google Scholar 

  3. Dietch JT, Jennings RK: Journal of Clinical Psychiatry 49:184–188, 1988.

    Google Scholar 

  4. Walsh MT, Dinan TG: Selective serotonin reuptake inhibitors and violence: A review of the available evidence. Acta Psychiatrica Scandinavica 104(2):84–91, 2001.

    Google Scholar 

  5. Convit A, Isay D, Otis D, et al: Characteristics of repeatedly assaultive psychiatric inpatients. Hospital and Community Psychiatry 41:1112–1115, 1990.

    Google Scholar 

  6. Owen C, Tarantello C, Jones M, et al: Repetitively violent patients in psychiatric units. Psychiatric Services 49(11):1458–1461, 1998.

    Google Scholar 

  7. Regier DA, Farmer ME, Rae DS, et al: Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 264:2511–2518, 1990.

    Google Scholar 

  8. Swanson JW: Mental disorder, substance abuse, and community violence: An epidemiological approach, in Violence and Mental Disorder: Developments in Risk Assessment. Edited by Monahan J, Steadman HJ. Chicago, The University of Chicago Press, 1994.

    Google Scholar 

  9. Link BG, Cullen FT, Andrews H: The violent and illegal behavior of mental patients reconsidered. American Sociological Review 57:275–292, 1992.

    Google Scholar 

  10. Link BG, Stueve A: Psychotic symptoms and the violent/illegal behavior of mental patients compared to community controls, in Violence and Mental Disorder: Developments in Risk Assessment. Edited by Monahan J, Steadman HJ. Chicago, The University of Chicago Press, 1994.

    Google Scholar 

  11. Steadman HJ, Mulvey EP, Monahan J, et al: Violence by people discharged from acute psychiatric inpatient facilities and others in the same neighborhoods. Archives of General Psychiatry 55:393–401, 1998.

    Google Scholar 

  12. Czobor P, Volavka J: Violence in the mentally ill: Questions remain [Letter]. Archives of General Psychiatry 56:193, 1999.

    Google Scholar 

  13. Binder RL, McNiel DE: Effects of diagnosis and context on dangerousness. American Journal of Psychiatry 145:728–732, 1988.

    Google Scholar 

  14. Tanke ED, Yesavage JA: Characteristics of assaultive patients who do and do not provide visible cues of potential violence. American Journal of Psychiatry 142:1409–1413, 1985.

    Google Scholar 

  15. Holden C: Paul MacLean and the triune brain. Science 204:1066–1068, 1979.

    Google Scholar 

  16. MacLean PD: The triune brain in conflict. Psychotherapy and Psychosomatics 28:207–220, 1977.

    Google Scholar 

  17. MacLean PD: Brain evolution relating to family, play, and the separation call. Archives of General Psychiatry. 42:405–417, 1985.

    Google Scholar 

  18. MacLean PD: Evolutionary psychiatry and the triune brain. Psychological Medicine 15:219–221, 1985.

    Google Scholar 

  19. Lindenmayer JP: The pathophysiology of agitation. Journal of Clinical Psychiatry. 2000;61(Suppl. 14):5–10, 2000.

    Google Scholar 

  20. Link BG, Stueve A, Phelan J: Psychotic symptoms and violent behaviors: Probing the components of “threat/control-override” symptoms. Social Psychiatry and Psychiatric Epidemiology 33(Suppl. 1):S55–S60, 1998.

    Google Scholar 

  21. Citrome L, Volavka J: Clinical management of persistent aggressive behavior in schizophrenia. Part II: Long-term pharmacotherapeutic strategies. Essential Psychopharmacology 5(1):17–30, 2002.

    Google Scholar 

  22. Citrome L, Volavka J: Atypical antipsychotics—Revolutionary or incremental advance? Expert Review of Neurotherapeutics 2(1):69–88, 2002.

    Google Scholar 

  23. Citrome L, Green L: The dangerous agitated patient: What to do right now. Postgraduate Medicine 87:231–236, 1990.

    Google Scholar 

  24. Salzman C: Use of benzodiazepines to control disruptive behavior in inpatients. Journal of Clinical Psychiatry 49(Suppl. 12):13–15, 1988.

    Google Scholar 

  25. Greenblatt DJ, Divoll M, Harmatz JS, et al: Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. Journal of Pharmaceutical Sciences 71:248–252, 1982.

    Google Scholar 

  26. Greenblatt DJ, Shader RI, Franke K, et al: Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. Journal of Pharmaceutical Sciences 68:57–63, 1979.

    Google Scholar 

  27. Clinton JE, Sterner S, Stelmachers Z, et al: Haloperidol for sedation of disruptive emergency patients. Annals of Emergency Medicine 16:319–322, 1987.

    Google Scholar 

  28. Thomas H, Schwartz E, Petrilli R: Droperidol versus haloperidol for chemical restraint of agitated and combative patients. Annals of Emergency Medicine 21:407–413, 1992.

    Google Scholar 

  29. Shale JH, Shale CM, Mastin WD: A review of the safety and efficacy of droperidol for the rapid sedation of severely agitated and violent patients. Journal of Clinical Psychiatry 64(5):500–505, 2003.

    Google Scholar 

  30. Lischke V, Behne M, Doelken P, et al: Droperidol causes a dose-dependent prolongation of the QT interval. Anesthesia and Analgesia 79:983–986, 1994.

    Google Scholar 

  31. Battaglia J, Moss S, Rush J, et al: Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. American Journal of Emergency Medicine 15(4):335–340, 1997.

    Google Scholar 

  32. Hughes DH: Acute psychopharmacological management of the aggressive psychotic patient. Psychiatric Services 50:1135–1137, 1999.

    Google Scholar 

  33. Currier GW, Simpson GM: Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. Journal of Clinical Psychiatry 62(3):153–157, 2001.

    Google Scholar 

  34. Currier GW, Chou JC, Feifel D, et al: Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidal and lorazepam. Journal of Clinical Psychiatry 65(3):386–394, 2004.

    Google Scholar 

  35. Baker RW, Kinon BJ, Maguire GA, et al: Effectiveness of rapid initial dose escalation of up to 40 mg per day of oral olanzapine in acute agitation. Journal of Clinical Psychopharmacology 23(4):342–348, 2003.

    Google Scholar 

  36. Lesem MD, Zajecka JM, Swift RH, et al: Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. Journal of Clinical Psychiatry 62:12–18, 2001.

    Google Scholar 

  37. Daniel DG, Potkin SG, Reeves KR, et al: Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: A double-blind, randomized trial. Psychopharmacology (Berlin) 155:128–134, 2001.

    Google Scholar 

  38. Pfizer, Inc: Briefing Document for Ziprasidone Mesylate for Intramuscular Injection, FDA Psychopharmacological Drugs Advisory Committee, February 15, 2001 (available at www.fda.gov).

  39. Brook S, Lucey JV, Gunn KP: Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Journal of Clinical Psychiatry 61(12):933–941, 2000.

    Google Scholar 

  40. Brook, S: Intramuscular ziprasidone: Moving beyond the conventional in the treatment of acute agitation in schizophrenia. Journal of Clinical Psychiatry 64(suppl 19):13–18, 2003.

    Google Scholar 

  41. Eli Lilly and Company: Briefing Document for Zyprexa IntraMuscular (olanzapine for injection), FDA Psychopharmacological Drugs Advisory Committee, January 11, 2001, with Addendum February 14, 2001 (available at www.fda.gov).

  42. Wright P, Birkett M, David SR, et al: Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. American Journal of Psychiatry 158:1149–1151, 2001.

    Google Scholar 

  43. Breier A, Meehan K, Birkett M, et al: A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of General Psychiatry 59(5):441–448, 2002.

    Google Scholar 

  44. Meehan K, Zhang F, David S, et al: A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. Journal of Clinical Psychopharmacology 21:389–397, 2001.

    Google Scholar 

  45. Meehan KM, Wang H, David SR, et al: Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: A double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 26(4):494–504, 2002.

    Google Scholar 

  46. Battaglia J, Lindborg SR, Alaka K, et al: Calming versus sedative effects of intramuscular olanzapine in agitated patients. American Journal of Emergency Medicine 21(3):192–198, 2003.

    Google Scholar 

  47. Lindborg SR, Beasley CM, Alaka K, et al: Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients. Psychiatry Research 119(1–2):113–123, 2003.

    Google Scholar 

  48. Wright P, Meehan K, Birkett M, et al: A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. Clinical Therapeutics 25(5):1420–1428, 2003.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Leslie Citrome.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Citrome, L. New Treatments for Agitation. Psychiatr Q 75, 197–213 (2004). https://doi.org/10.1023/B:PSAQ.0000031791.53142.85

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/B:PSAQ.0000031791.53142.85

Navigation